Glenmark Life Sciences Ltd.

View in App
576.55 -5.25 ▼-0.9%

08 June 2023, 04:01:00 PM
Volume: 36,556

Company Profile

View details >>
Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.glenmarklifesciences.com
Market Cap 7,064.30 Cr.
Enterprise Value(EV) 6,754.91 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 38.11 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 15.13 Trailing Twelve Months Ending 2023-03
Industry PE 33.65 Trailing Twelve Months Ending 2023-03
Book Value / Share 174.51 Trailing Twelve Months Ending 2023-03
Price to Book Value 3.30 Calculated using Price: 576.55
Dividend Yield 3.64 Period Ending 2022-03
No. of Shares Subscribed 12.25 Cr. 122,527,172 Shares
FaceValue 2
About Glenmark Life Sciences Ltd.
The company is in the business of making high-quality drugs by unlocking the possibilities of science.

Glenmark Life Sciences Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Glenmark Life Sciences Ltd. Performance

View details >>
1 Day
-0.90%
1 Week
+6.35%
1 Month
+6.56%
3 Month
+49.21%
6 Month
+34.30%
1 Year
+24.65%
2 Year
5 Year
10 Year

Glenmark Life Sciences Ltd. Fundamental Ratios

View details >>
5 years 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 451.05 127.84 60.91 29.87
Return on Capital Employed (%) 527.74 185.60 96.75 42.24
Return on Assets (%) -510.59 26.51 19.56 17.82 16.57

Glenmark Life Sciences Ltd. Balance Sheet

View details >>
Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr.
Shh. Funds -1 88 402 753 2,054 2,138
Non Curr. Liab. 7 16 23 33 60
Curr. Liab. 1 1,380 1,307 1,445 747 504
Minority Int.
Equity & Liab. 0 1,475 1,726 2,221 2,834 2,702
Non Curr. Assets 545 565 598 706 852
Curr. Assets 0 931 1,160 1,623 2,127 1,850
Misc. Exp. not W/O
Total Assets 0 1,475 1,726 2,221 2,834 2,702

Glenmark Life Sciences Ltd. Profit and Loss

View details >>
Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. TTM
Net Sales 0 886 1,537 1,885 2,123 2,161
Other Income 1 12 1 15 29
Total Income 0 887 1,549 1,886 2,138 2,190
Total Expenditure 0 -639 -1,065 -1,294 -1,507 -1,519
PBIDT 0 248 484 592 631 671
Interest -1 -34 -88 -28 -1
Depreciation -19 -29 -33 -38 -42
Taxation 0 -33 -108 -119 -146 -162
Exceptional Items
PAT 0 196 313 352 419 467
Adjusted EPS -8 18 29 33 34 38

Glenmark Life Sciences Ltd. Cash Flow

View details >>
Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 10 195 388 598
Cash Fr. Inv. -9 -51 -69 -122
Cash Fr. Finan. 0 1 -137 -214 -79
Net Change 0 2 8 106 397
Cash & Cash Eqvt 0 2 10 116 512

Glenmark Life Sciences Ltd. Shareholding Pattern

View details >>
7 Qtrs 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%)
Promoter 82.84 82.85 82.85 82.85 82.85 82.85 82.85
Public 17.16 17.15 17.15 17.15 17.15 17.15 17.15
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Glenmark Life Sciences Ltd. Announcements

View details >>
Thu, 18 May 2023
Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are attaching herewith the Annual Secretarial Compliance Report for the financial year 2022-23.
Fri, 12 May 2023
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited Monitoring Agency for the quarter ended 31st March 2023 in respect of utilization of proceeds of the IPO of the Company.
Tue, 02 May 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the transcript of the Earnings call held on Friday April 28 2023 for the Fourth quarter and year ended March 31 2023 is available on the Companys website at:https://www.glenmarklifesciences.com/pdf/Earnings%20Call%20Transcript_28_April_2023.pdfThe said transcript is also attached.

Glenmark Life Sciences Ltd. Technical Scans

View details >>
Thu, 08 Jun 2023
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Above Last Week High Close Above Last Week High

Glenmark Life Sciences Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 236,838.35 987.10 -2.7%
Divi's Laboratories Ltd. 92,904.71 3,499.65 -1.2%
Cipla Ltd. 77,933.48 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. 77,441.55 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. 70,842.70 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. 60,989.56 1,802.05 +0.0%
Mankind Pharma Ltd. 58,646.15 1,464.00 -1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 27.95 987.10 -2.7%
Divi's Laboratories Ltd. Consolidated 2023-03 50.95 3,499.65 -1.2%
Cipla Ltd. Consolidated 2023-03 27.81 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 17.18 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 86.49 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 48.99 1,802.05 +0.0%
Mankind Pharma Ltd. Consolidated 2023-03 45.75 1,464.00 -1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.23 987.10 -2.7%
Divi's Laboratories Ltd. Consolidated 2023-03 7.28 3,499.65 -1.2%
Cipla Ltd. Consolidated 2023-03 3.33 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.33 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 11.45 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9.84 1,802.05 +0.0%
Mankind Pharma Ltd. Consolidated 2023-03 4.99 1,464.00 -1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 987.10 -2.7%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,499.65 -1.2%
Cipla Ltd. Consolidated 2022-03 0.04 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,802.05 +0.0%
Mankind Pharma Ltd. Consolidated 2022-03 0.14 1,464.00 -1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 987.10 -2.7%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,499.65 -1.2%
Cipla Ltd. Consolidated 2022-03 13.10 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,802.05 +0.0%
Mankind Pharma Ltd. Consolidated 2022-03 26.72 1,464.00 -1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 987.10 -2.7%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,499.65 -1.2%
Cipla Ltd. Consolidated 2022-03 13.10 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,802.05 +0.0%
Mankind Pharma Ltd. Consolidated 2022-03 26.72 1,464.00 -1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 987.10 -2.7%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,499.65 -1.2%
Cipla Ltd. Consolidated 2022-03 21,763.34 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,802.05 +0.0%
Mankind Pharma Ltd. Consolidated 2022-03 7,781.56 1,464.00 -1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 987.10 -2.7%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,499.65 -1.2%
Cipla Ltd. Consolidated 2022-03 2,559.47 965.45 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,649.90 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,927.00 -2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,802.05 +0.0%
Mankind Pharma Ltd. Consolidated 2022-03 1,452.96 1,464.00 -1.5%

Glenmark Life Sciences Ltd. FAQ's

What is Glenmark Life Scienc share price?
Can I buy Glenmark Life Scienc shares now?
What is the Dividend Yield of Glenmark Life Scienc?
What is the Market Cap of Glenmark Life Scienc?
What are the key metrics to analyse Glenmark Life Scienc?
What is the 52 Week High and Low of Glenmark Life Scienc?
What is the trend of Glenmark Life Scienc share price?